Firestone Karen 4

What Happened
Karen Firestone, a director of Amylyx Pharmaceuticals (AMLX), reported an open-market purchase of 3,800 shares on 2026-05-21 at $13.51 per share, for a total of $51,338. This was a purchase (Form 4 transaction code P), which investors often view as more informative than routine sales.

Key Details

• Transaction date: 2026-05-21
• Transaction type: Open-market purchase (Code P)
• Price per share: $13.51
• Shares acquired: 3,800
• Total value: $51,338
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnotes/plan: No 10b5-1 plan, tax-withholding, or other footnotes indicated in the provided data
• Timeliness: Report filed 2026-05-26 (transaction on 2026-05-21) — filing appears late relative to the usual 2-business-day Form 4 deadline

Context
Purchases by directors are often interpreted as a signal of confidence, though they do not prove future performance. The filing does not show any derivatives, exercises, gifts, or immediate sales tied to this purchase. The delayed filing means the market received the disclosure later than standard — investors should factor timing when using this report for decision-making.